Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

935 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
TIGIT blockade repolarizes AML-associated TIGIT+ M2 macrophages to an M1 phenotype and increases CD47-mediated phagocytosis.
Brauneck F, Fischer B, Witt M, Muschhammer J, Oelrich J, da Costa Avelar PH, Tsoka S, Bullinger L, Seubert E, Smit DJ, Bokemeyer C, Ackermann C, Wellbrock J, Haag F, Fiedler W. Brauneck F, et al. Among authors: bokemeyer c. J Immunother Cancer. 2022 Dec;10(12):e004794. doi: 10.1136/jitc-2022-004794. J Immunother Cancer. 2022. PMID: 36549780 Free PMC article.
Molecular response patterns in relapsed/refractory AML patients treated with selinexor and chemotherapy.
Klement P, Fiedler W, Gabdoulline R, Dallmann LK, Wienecke CP, Schiller J, Kandziora C, Teich K, Heida B, Büttner K, Brandes M, Funke C, Wichmann M, Othman B, Chromik J, Amberg S, Kebenko M, Schlipfenbacher V, Wilke AC, Modemann F, Janning M, Serve H, Bokemeyer C, Theile S, Deppermann U, Kranich AL, Ganser A, Thol F, Heuser M. Klement P, et al. Among authors: bokemeyer c. Ann Hematol. 2023 Feb;102(2):323-328. doi: 10.1007/s00277-022-05075-4. Epub 2022 Dec 28. Ann Hematol. 2023. PMID: 36576532 Free PMC article.
Immunosuppressive M2 TAMs represent a promising target population to enhance phagocytosis of ovarian cancer cells in vitro.
Brauneck F, Oliveira-Ferrer L, Muschhammer J, Sturmheit T, Ackermann C, Haag F, Schulze Zur Wiesch J, Ding Y, Qi M, Hell L, Schmalfeldt B, Bokemeyer C, Fiedler W, Wellbrock J. Brauneck F, et al. Among authors: bokemeyer c. Front Immunol. 2023 Oct 2;14:1250258. doi: 10.3389/fimmu.2023.1250258. eCollection 2023. Front Immunol. 2023. PMID: 37876933 Free PMC article.
Misuse of tumor marker levels leads to an insufficient International Germ Cell Consensus Classification (IGCCCG) risk group assignment and impaired treatment.
Majewski M, Paffenholz P, Ruf C, Che Y, Seidel C, Heinzelbecker J, Schmelz HU, Matthies C, Albers P, Bokemeyer C, Heidenreich A, Pichler M, Nestler T; GTCSG (German Testicular Cancer Study Group). Majewski M, et al. Among authors: bokemeyer c. Cancer Med. 2023 Aug;12(16):16829-16836. doi: 10.1002/cam4.6304. Epub 2023 Jul 1. Cancer Med. 2023. PMID: 37392170 Free PMC article.
935 results